ang ii  (Proteintech)

Journal: Clinical Science (London, England : 1979)

Article Title: Increased absorptive transcytosis and tight junction weakness in heart failure are equally corrected by exercise training and losartan

doi: 10.1042/CS20242965

Figure Lengend Snippet: (A) Representative PVN images illustrating Ang II (red) and IBA-1 immunoreactivity (green) within the ventromedial nucleus (superimposed rectangle) in which measurements were made. The small square indicates the microglial cell whose magnified images (insets at right) depict Ang II-microglia colocalization (yellow) in soma and processes as analyzed in merged pictures (upper corner) or quantified by means of superimposed binary images (lower corner). Scale bar: 50 μm. 3V, third cerebral ventricle. Bar graphs at the right indicate the quantitative analysis of Ang II ( B ) and IBA-1 ( C ) immunoreactivity and the colocalization of both ( D ). Comparisons made by two-way factorial ANOVA. Values are means of six to eight slices/rat/four rats/group. an g II: group F(1,12)=67.98, P <0.001; condition F(1,12)=18.41, P= 0.001; interaction F(1,12)=15.38, P =0.002. IBA-1: group F(1,12)=13.93, P= 0.003; condition F(1,12)=79.23, P< 0.001; interaction F(1,12)=25.47, P <0.001. Colocalization: group F(1,12)=74.00, P <0.001; condition F(1,12)=50.67, P< 0.001; interaction F(1,12)=23.48, P <0.001. Significances ( P <0.05): * vs . Veh-S; † vs . Veh-T. PVN, paraventricular hypothalamic nucleus.

Article Snippet: Some slices suspended in 0.3% Triton X-100 in 2% donkey serum were also incubated for 48 h with polyclonal goat anti-Ang II type 1 receptor primary antibody (AT 1 R, 1:500 dilution, Santa Cruz Biotechnology, Cat. no. AT1 (N-10)-G: sc-1173-G), an antibody raised against a peptide mapping within the N-terminal extracellular domain of the human AT 1 R, followed by the incubation with the secondary antibody anti-goat Alexa Fluor 594, Cat. no. 705–585-003, 1:500 dilution, Jackson ImmunoResearch) for 90 min.

Techniques:

Journal: Clinical Science (London, England : 1979)

Article Title: Increased absorptive transcytosis and tight junction weakness in heart failure are equally corrected by exercise training and losartan

doi: 10.1042/CS20242965

Figure Lengend Snippet: Representative PVN images illustrating AT 1 R (red) and IBA-1 immunoreactivity (green) within the within the PVN vm (superimposed rectangle). The small square indicates the microglial cell whose magnified images (insets at right) depict Ang II-microglia colocalization (yellow) in soma and processes in merged pictures (right upper corner) and the superimposed binary images (right lower corner). Scale bar: 50 μm. 3V, third cerebral ventricle; PVN, paraventricular hypothalamic nucleus.

Article Snippet: Some slices suspended in 0.3% Triton X-100 in 2% donkey serum were also incubated for 48 h with polyclonal goat anti-Ang II type 1 receptor primary antibody (AT 1 R, 1:500 dilution, Santa Cruz Biotechnology, Cat. no. AT1 (N-10)-G: sc-1173-G), an antibody raised against a peptide mapping within the N-terminal extracellular domain of the human AT 1 R, followed by the incubation with the secondary antibody anti-goat Alexa Fluor 594, Cat. no. 705–585-003, 1:500 dilution, Jackson ImmunoResearch) for 90 min.

Techniques:

Journal: Clinical Science (London, England : 1979)

Article Title: Increased absorptive transcytosis and tight junction weakness in heart failure are equally corrected by exercise training and losartan

doi: 10.1042/CS20242965

Figure Lengend Snippet: Plots in panels A–D were made with values obtained in a large number of capillaries, Ang II, and IBA-1 double-labeled slices, whereas panels E and F were made with autonomic measurements in each rat and its respective mean Ang II immunoreactivity. Linear regression equations, correlation coefficients, and P values are Vesicles/capillary × Ang II Y = 0.70 × –1.12, r = 0.895, P <0,001; TJ/capillary border × Ang II Y = –2.36 × + 94.94, r = 0.881, P <0,001; IBA-1 if × Ang II Y = 0.64 × + 6.29, r = 0.855, P <0,001; FITC leakage × Ang II Y = 0.47 × –1.18, R = 0.824, P <0,001; LF-SAP × Ang II Y = 0.43 × –0.34, R = 0.889, P <0,001; SAP variability × Ang II Y = 1.27 × + 0.53, r = 0.935, P <0,001. * denotes a significant correlation. BBB, blood–brain barrier; SAP, systolic arterial pressure; TJ, tight junction.

Article Snippet: Some slices suspended in 0.3% Triton X-100 in 2% donkey serum were also incubated for 48 h with polyclonal goat anti-Ang II type 1 receptor primary antibody (AT 1 R, 1:500 dilution, Santa Cruz Biotechnology, Cat. no. AT1 (N-10)-G: sc-1173-G), an antibody raised against a peptide mapping within the N-terminal extracellular domain of the human AT 1 R, followed by the incubation with the secondary antibody anti-goat Alexa Fluor 594, Cat. no. 705–585-003, 1:500 dilution, Jackson ImmunoResearch) for 90 min.

Techniques: Labeling

Journal: Clinical Science (London, England : 1979)

Article Title: Increased absorptive transcytosis and tight junction weakness in heart failure are equally corrected by exercise training and losartan

doi: 10.1042/CS20242965

Figure Lengend Snippet: Schematic drawing depicting main effects of angiotensin II availability on blood–brain barrier (BBB), microglia morphology/activity, and sympathetic activity in heart failure (HF) rats treated with vehicle (Veh) or losartan (Los) and submitted to sedentary (S) or training (T) protocol.

Article Snippet: Some slices suspended in 0.3% Triton X-100 in 2% donkey serum were also incubated for 48 h with polyclonal goat anti-Ang II type 1 receptor primary antibody (AT 1 R, 1:500 dilution, Santa Cruz Biotechnology, Cat. no. AT1 (N-10)-G: sc-1173-G), an antibody raised against a peptide mapping within the N-terminal extracellular domain of the human AT 1 R, followed by the incubation with the secondary antibody anti-goat Alexa Fluor 594, Cat. no. 705–585-003, 1:500 dilution, Jackson ImmunoResearch) for 90 min.

Techniques: Activity Assay